加强印度对抗Mycobacterium Tuberculosis的卫生安全工作:差距和机遇
Abhijit Poddar1, Sourik Mukherjee1, S R Rao1
1Abhijit Poddar, PhD, is Chief, Centre for Bio-Policy Research (CBPR), Mahatma Gandhi Medical Advanced Research Institute (MGMARI), Sri Balaji Vidyapeeth (Deemed-to-be-University), Pondicherry, India, and co-founder of Genentech Regulatory Solutions LLP, Hyderabad, India. Sourik Mukherjee, MSc, is a Research Scholar, MGMARI, Sri Balaji Vidyapeeth (Deemed-to-be-University), Pondicherry, India. S. R. Rao, PhD, is Founder and Director, Genentech Regulatory Solutions LLP, Hyderabad, India, and Former Senior Advisor, Department of Biotechnology, Ministry of Science and Technology, Government of India, New Delhi, India.
印度面临着相当大的结核病 (TB) 负担,并致力于在2025年之前消除. 然而,药物耐药性和基础设施薄弱等持续挑战需要修订,以证据为基础的战略与全球目标保持一致.
科学领域:
- 公共卫生 公共卫生
- 传染性疾病 传染性疾病
- 全球卫生安全 全球卫生安全
背景情况:
- 印度承担了全球结核病 (TB) 负担的四分之一.
- 该国设定了一个雄心勃勃的目标,到2025年消除结核病,超过全球目标.
- 尽管有像Pradhan Mantri TB Mukt Bharat Abhiyan这样的公共卫生倡议,但进展仍受到持续挑战的威胁.
研究的目的:
- 突出影响印度结核病消除的未得到解决的卫生安全挑战.
- 倡导修订的结核病消除战略,与全球2030年目标保持一致.
- 强调需要基于证据的政策和多部门协调.
主要方法:
- 审查印度现有的结核病消除战略及其局限性.
- 确定关键的健康安全挑战,包括多药耐药结核病和生物安全性低下.
- 对影响结核病控制的环境和社会决定因素的分析.
主要成果:
- 持续面临的挑战包括数据透明度问题,过度负担的医疗保健系统和不切实际的时间表.
- 没有充分解决的问题包括多药耐药结核病,生物安全性低下,缺乏治疗后监测,环境因素以及针对弱势群体的不足策略.
- 目前的战略可能不足以实现雄心勃勃的2025年消除目标.
结论:
- 对消除结核病的修订方法对印度至关重要.
- 成功的关键要素包括基于证据的政策,改进的监督,劳动力支持和多部门协调.
- 环境和技术干预对于全面控制和消除结核病至关重要.
更多相关视频
10:04Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
Published on: September 5, 2017
10:29A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
Published on: March 24, 2017
相关概念视频
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
